The EU pharmaceutical package is set to reshape the European life sciences landscape, introducing significant reforms around data exclusivity, compulsory licences, and SPCs. With ongoing negotiations and key provisions still under debate, this reform presents both opportunities and uncertainties for patent enforcement and market strategy. Join leading experts to understand the implications of these regulatory changes and how in house counsel can adapt their litigation strategies accordingly.

• Review proposed changes to data exclusivity periods and their impact on generic market access and innovation incentives.
• Examine the introduction of compulsory licences in emergency situations and the potential risks and benefits for patent holders.
• Explore the push for a centralised unitary SPC system across Europe and what this means for patent protection harmonisation.
• Discuss how these reforms might influence competition, supply security, and environmental requirements in the pharmaceutical sector.

With the introduction of the UPC and shifting dynamics in global patent enforcement, life science companies face renewed questions about when to settle, when to litigate, and how to choose the right forum. This candid, cross-sector panel of in-house counsel and litigators will explore how dispute resolution strategy is evolving across the industry.

• Discover how in-house teams weigh the risks and rewards of litigation versus settlement in a post-UPC world.
• Determine whether certain sectors - such as biotech, generics, or medtech - are more inclined to settle and why.
• Discuss practical insights on how to structure licensing negotiations or parallel proceedings to support favourable outcomes.

The UPC was met with caution by the life science sector. Nevertheless, new data from its first two years shows a changing reality - pharmaceutical and chemistry-related litigation is not only present, it’s gaining momentum. This session will offer a deep dive into the UPC’s evolving role in high-stakes life science patent disputes, helping you prepare an informed strategy for 2025 and beyond.

• Understand the latest UPC litigation statistics and what they reveal about pharma and chemistry sector adoption.
• Discover why Milan and Munich are emerging as key venues for life science disputes and what it means for your forum selection.
• Learn how English-language dominance is shaping litigation strategy for multinational teams.
• Analyse how early UPC case law is influencing industry confidence and what your business risks by staying on the sidelines.
• Hear how to coordinate UPC proceedings with EPO oppositions to build an integrated and effective litigation approach.

As patent enforcement strategies face growing scrutiny, competition law is increasingly influencing how life science companies manage exclusivity and market access. This session will unpack recent court and authority decisions across Europe, Switzerland, and the United States, spotlighting how regulators are drawing the line between legitimate IP enforcement and anti-competitive conduct. From divisional strategy concerns in the Copaxone case to the exoneration of Novartis by COMCO, attendees will gain a nuanced understanding of evolving antitrust standards and how to adapt their own IP strategy accordingly.

• Analyse the implications of the Copaxone divisional strategy case and what it signals about future antitrust enforcement in the context of IP gaming.
• Understand why COMCO cleared the Cosentyx® patent portfolio case and what it reveals about balancing freedom to operate and competition law.
• Explore the intersection of U.S. antitrust enforcement with FDA listing practices delistings, ANDA exclusivity, and the shifting impact of FTC and Federal Circuit decisions.
• Examine how China’s recent implementation of ANDA litigation and patent linkage modeled on the U.S. Hatch-Waxman system - is impacting exclusivity, competition, and antitrust scrutiny in both jurisdictions.

Injunctions can be decisive in life sciences patent litigation, particularly in fast-moving markets. This session delivers a strategic overview of recent developments in preliminary injunctions across the UPC, Europe, and the United States, helping patent holders and challengers alike prepare for high-stakes enforcement in 2025. With a cross-border perspective, expert speakers will unpack emerging trends, legal thresholds, and jurisdictional contrasts shaping the availability and strength of injunctive relief.

• Explore the latest PI case law from the UPC, key EU countries, and the USA and how it impacts pharma and biotech strategies.
• Understand practical approaches for securing or resisting injunctions in different jurisdictions, including timing, evidence, and risk assessment.
• Gain actionable insights on how PI outcomes are influencing broader litigation and market entry planning in the life sciences.

Patent Litigation Case Law Review.